Determination of class G antibodies to SARS-CoV2 after application of ‘GamCOVID-Vac’ or ‘Sputnik V’ vaccine of National Research Centre for Epidemiology and Microbiology n.a. honorary academician N.F. Gamaleya

In the context of the global spread of the new coronavirus infection, studies aimed at investigating formation of anti-infectious and post-vaccination immunity are of special importance, which is necessary to prevent and reduce morbidity and mortality due to SARS-CoV-2 infection.Purpose: to assess anti-infectious immunity against SARS-COV-2 in various forms of the disease and development of post-vaccination humoral reactions in medical workers of the perinatal center. Materials and methods. A study of blood serum was carried out to assess SARS-CoV-2-specific IgM and IgG antibodies in 119 medical workers recovered after COVID-19, divided into groups based on the disease severity (mild, moderate and asymptomatic), as well as in 62 vaccinated employees, divided into groups according to age. Semi-quantitative measurement of virus-specific antibodies was carried out by ELISA with test systems "SARS-COV-2-IgG-ELISA-BEST" and "SARS-COV-2-IgM-ELISA-BEST".Statistical processing of the research results was carried out using Microsoft Excel 2010 and Statistica 6. Quantitative characteristics were presented as median (ME), lower and upper quartiles (LQ1-UQ3); qualitative parameters – as absolute value and relative number (%). Difference between groups was analyzed by using the χ2 test (qualitative) and the Mann-Whitney U-test (quantitative).Results. The results of the study showed that the majority of employees with a moderate-severe form of SARS-COV-2 had a high level of IgG (PR - a positivity rate of more than 9.0 arbitrary units) 9 months after the disease compared to those who suffered from mild or asymptomatic (83.3% versus 25.8% and 13.3%, p 0.017) infection. The duration of IgG circulation after former illness had no relation to its severity and patient age. The effectiveness of the primary vaccination "Sputnik V" and revaccination with "Sputnik Light" and "KoviVak" was 100% after inoculating the vaccine second component. The lowest level of antibodies after the first vaccination is recorded in persons over 60 years old (1.48 (1.12-3.25 versus PR = 8.48 (5.78-10.11) and 9.27 (5.84-10, 31) arbitrary units, p 0.017)), in comparison with young and middle-age subjects. The speed SARS-COV-2 elimination of IgG at 6, 9 or more months after vaccination depends on relevant initial peak antibody concentration. Subjects who were initially vaccinated with the KoviVac vaccine, IgG was not detected 2 months after vaccination. The protective effect of "Sputnik V", "Sputnik Light", "KoviVac" after re-infection with SARS-COV-2 averages 71.2%. Conclusion. Thus, the results obtained on assessing anti-infectious and post-vaccination immunity against SARS-CoV-2 emphasize the need for further studies on a larger patient cohort, especially in those with asymptomatic infection as well as the elderly subjects.

show abstract

Formation of anti-infectious and post-vaccination anti-SARS-CoV-2 humoral immunity in medical workers of the perinatal center

Chistyakova

Malgina

Ремизова

et al. 2022

Russian Journal of Infection and Immunity

View full text Add to dashboard Cite

show abstract

Thrombosis in unvaccinated and Gam-COVID-Vac-vaccinated patients with COVID-19

et al. 2022

View full text Add to dashboard Cite

Aim. To analyze the incidence of thrombotic events in unvaccinated and GamCOVID-Vac-vaccinated patients with coronavirus disease 2019 (COVID-19).Material and methods. This prospective study included 316 patients (group 1) vaccinated with two doses of Sputnik V (Gam-COVID-Vac) hospitalized between November 20, 2020 and June 1, 2021 for COVID-19. Group 2 included 754 unvaccinated patients with a positive polymerase chain reaction test for SARSCoV-2.Results. During inhospital period, deaths were recorded only in unvaccinated patients (group 1 — 0%; group 2 — 10,7% (n=87); p<0,0001). Among unvaccinated patients, the following thrombotic events were more common: upper- extremity deep vein thrombosis (group 1 — 0,63% (n=2); group 2 — 5,4% (n=41); p=0,0003), lower-extremity deep vein thrombosis (group 1 — 2,21% (n=7); group 2 — 11,4% (n=86); p<0,0001), pulmonary embolism (PE) (group 1 — 0%; group 2 — 3,4% (n=26); p=0,0008), lower limb arterial thrombosis followed by thrombectomy (group 1 — 0,31% (n=1); group 2 — 12% (n=91); p <0,0001), lower limb arterial retrombosis after retrombectomy (group 1 — 0,31% (n=1); group 2 — 8,7% (n=66); p<0,0001), lower limb amputation (group 1 — 0%; group 2 — 8,7% (n=66); p<0,0001), composite endpoint (group 1 — 3,8% (n=12); group 2 — 55,2% (n=416); p<0,0001). In the long-term follow-up period (125,5±26,5 days), recurrent COVID-19 developed significantly more often in unvaccinated patients (group 1 — 0,63% (n=2); group 2 — 3,6% (n=24); p=0,007). All arterial and venous thromboses, limb amputations were diagnosed only among unvaccinated patients.Conclusion. Vaccination with Sputnik V (Gam-COVID-Vak) prevents the severe COVID-19 with the development of deaths, pulmonary embolism, venous and arterial thrombosis.

show abstract

Arterial and venous thromboses in patients with COVID-19 vaccined with Sputnik V vaccine

Kazantsev,

Korotkikh,

Taits

et al. 2023

Kardiol. serdechno-sosud. khir.

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Determination of class G antibodies to SARS-CoV2 after application of ‘GamCOVID-Vac’ or ‘Sputnik V’ vaccine of National Research Centre for Epidemiology and Microbiology n.a. honorary academician N.F. Gamaleya

Cited by 6 publications

References 2 publications

Formation of anti-infectious and post-vaccination anti-SARS-CoV-2 humoral immunity in medical workers of the perinatal center

Formation of anti-infectious and post-vaccination anti-SARS-CoV-2 humoral immunity in medical workers of the perinatal center

Thrombosis in unvaccinated and Gam-COVID-Vac-vaccinated patients with COVID-19

Arterial and venous thromboses in patients with COVID-19 vaccined with Sputnik V vaccine

Contact Info

Product

Resources

About